Love Employee/iStock via Getty Images Antibody-drug conjugates (or ADCs) are enjoying a renaissance today, and as one of the leading independent developers of ADCs, Japan’s Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY)(4568.T) stands to benefit tremendously in the coming decade as lead drugs like Enhertu and Dato-DXd target $15B or more in annual potential revenue and fund a robust pipeline of next-gen assets that could offer even better efficacy and tolerability data. With celebrated clinical data and majo ...